🟢 Telix Pharmaceuticals is trading 4.74% up today after half-year revenue and EBITDA growth

Telix Pharmaceuticals is trading 4.74% up at A$16.36 after its August 20 half-year results showed US$477 million revenue and US$52 million adjusted EBITDA.

• Revenue rose 22% year over year, while adjusted EBITDA increased 146%.
• Management reaffirmed FY2026 revenue guidance of US$950–970 million and expects revenue plus other income above US$1 billion.
• The company disclosed a new at-the-market equity distribution facility; broader markets were largely flat, and no separate August 24 announcement was identified.